Amgen

Amgen is a global biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics for serious illnesses. Its product portfolio includes medicines in oncology, hematology, cardiovascular disease, inflammation, bone health and neuroscience, with well‑known brands such as Enbrel, Neulasta, Prolia and Kyprolis. The company serves patients and healthcare providers in more than 100 countries, focusing on treatments that address unmet medical needs through biologics and small‑molecule drugs.

Amgen reports a workforce of approximately 24,000 employees worldwide and generated annual revenues exceeding $26 billion in recent fiscal years. Its research and development operations are concentrated in facilities across the United States, Europe and Asia, supporting a pipeline that routinely advances multiple candidates into clinical trials each year. The firm’s manufacturing network supplies both its own products and those of partners through contract manufacturing arrangements, underscoring its integrated approach from discovery to distribution.

A distinguishing attribute of Amgen is its pioneering role in the development of recombinant DNA technology and its early success with erythropoietin‑stimulating agents, which helped establish the modern biologics industry. The company maintains a strong emphasis on pipeline depth, investing heavily in areas such as immuno‑oncology and cardiovascular therapeutics, and it frequently collaborates with academic institutions and other biotech firms to expand its scientific reach. Regulatory interactions are a core competency, as Amgen consistently navigates complex approval pathways with agencies like the FDA and EMA to bring novel therapies to market.

Amgen is an independent, publicly traded corporation listed on the NASDAQ under the ticker AMGN, with no parent company or controlling shareholder. Its governance structure includes a board of directors overseeing strategic direction, while executive leadership manages day‑to‑day operations across its global subsidiaries. The organization’s ownership is dispersed among institutional and individual investors, reflecting its status as a standalone entity in the biotechnology sector.